NCT05293600 Rescue Pharmacotherapy for OSA
| NCT ID | NCT05293600 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Brigham and Women's Hospital |
| Condition | Obstructive Sleep Apnea |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 70 participants in total. It began in 2023-07-01 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Persistent obstructive sleep apnea (OSA) is common in people treated with mandibular advancement device (MAD) or hypoglossal nerve stimulation (HGNS). For most patients, these treatments are the last line of defense. If MAD or HGNS do not work, then patients are left to suffer the consequences of undertreated OSA. In this study, the investigators want to test the addition of a drug treatment to their regimen. Endotypes will be targeted pharmacologically with one of the following drugs: acetazolamide for a high loop gain, atomoxetine-plus-eszopiclone for poor pharyngeal muscle compensation, or trazodone for a low arousal threshold. This aim is expected to provide treatment strategies for rescuing non-responders to MAD or HGNS therapy.
Eligibility Criteria
Inclusion Criteria: * Individuals who have failed MAD or HGNS therapy, defined as a residual AHI ≥ 15 events/hr on MAD or HGNS therapy. Exclusion Criteria: * Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: central sleep apnea (\>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 \< 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions. * Other sleep disorders: periodic limb movements (periodic limb movement index \> 20/hr), narcolepsy, or parasomnias. * Any unstable major medical condition. * Medications expected to stimulate or depress respiration (including opioids, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * Use of SSRIs/SNRIs. * Contraindications for atomoxetine, including: * pheochromocytoma * use of monoamine oxidase inhibitors * benign prostatic hypertrophy, urinary retention * untreated narrow angle glaucoma * bipolar disorder, mania, psychosis * clinically significant constipation, gastric retention * pre-existing seizure disorders * clinically-significant kidney disorders * clinically-significant liver disorders * clinically-significant cardiovascular conditions * severe hypertension (SBP\>180 mmHg or DBP\>110 mmHg measured at baseline) * cardiomyopathy (LVEF\<50%) or heart failure * advanced atherosclerosi * history of cerebrovascular events * history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation * other serious cardiac conditions that would raise the consequences of an increase in blood pressure or heart rate * myasthenia gravis * pregnancy/breast-feeding * Contraindications for eszopiclone, including: * Hypersensitivity to eszopiclone * Chronic Obstructive Pulmonary Disease (COPD) * Pregnancy * Breast feeding * Liver disease * Contraindications for acetazolamide, including: * Hyperchloremic acidosis * Hypokalemia * Hyponatremia * Adrenal insufficiency * Impaired kidney function * Hypersensitivity to acetazolamide or other sulfonamides. * Marked liver disease or impairment of liver function, including cirrhosis. * Contraindications for trazodone, including: * suicidal ideation * bipolar disorder, mania * use of monoamine oxidase inhibitors * coronary artery disease * cardiac arrhythmias * QT prolongation * hepatic disease * renal failure or impairment * closed angle glaucoma * priapism * pregnancy/breast-feeding
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05293600 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Obstructive Sleep Apnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05293600 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05293600 currently recruiting?
Yes, NCT05293600 is actively recruiting participants. Contact the research team at awellman@bwh.harvard.edu for enrollment information.
Where is the NCT05293600 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT05293600 clinical trial?
NCT05293600 is sponsored by Brigham and Women's Hospital. The trial plans to enroll 70 participants.